A box of medications Cerebral medical providers can prescribe.Cerebral SoftBank-backed telehealth startup Cerebral is under federal scrutiny for its prescribing practices. 30 interviews and over 2,000 documents suggest the company put growth ahead of patient safety. A Cerebral spokesperson said the reports represented a small fraction of patients and that the former nurse's comment is baseless. An online mental health startup that launched just ahead of the pandemic appears to have cast aside clinical psychiatry standards in the pursuit of growth, an investigation by Insider's Shelby Livingston and Blake Dodge has found.Cerebral, the SoftBank-backed telehealth company that raised $462 million in funding, is currently under investigation by federal agencies including the Department of Justice, the Drug Enforcement Administration, and the Federal Trade Commission.Now, a trove of internal documents including more than 2,000 incident reports and interviews with more than 30 current and former employees paint a detailed picture of Cerebral's business and medical practices.A spokesperson for Cerebral, Dan Childs, said in a statement to Insider that the volume of incident reports should be placed in context with the size of the company's patient population.